


# 4<sup>th</sup> ATLANTIC MELANOMA MEETING

LIVESTREAM RECORDING



## SCHEDULE

### Opening and welcome

45 minutes

#### Management of Brain Metastases in Melanoma

*Lara Best, MD, FRCPC, Medical Radiation Oncologist, St Stephen's Hospital, Hervey Bay, Australia & GenesisCare*

Learning objectives:

- Illustrate how number and volume of brain metastases impacts brain directed treatment decision making
- Compare systemic therapies with respect to how they can be leveraged to manage melanoma brain metastases
- Construct a management algorithm for patients presenting with melanoma brain metastases utilizing surgery, radiotherapy and systemic therapy
- Identify the current areas of controversy in management melanoma brain metastases

10 minutes

### Questions

30 minutes

#### Mohs Micrographic Surgery for the management of Basal Cell Carcinoma

*Michael Stevens, MD, FRCPC, Assistant Professor, Division of Clinical Dermatology & Cutaneous Science, Department of Medicine, Dalhousie University*

Learning objectives:

- Gain a better understanding of what Mohs Micrographic Surgery is and how it is used
- Understand how Mohs Micrographic Surgery can help your patients
- Learn how to directly access Mohs Micrographic Surgery for your patients

10 minutes

### Questions

20 minutes

#### Management of Advance Stage Basal Cell Carcinoma

*Ceillidh MacPhail MD, MSc, Resident, Medical Oncology, QEII Health Sciences Centre*

Learning objectives:

- Review the evidence for vismodegib in locally advanced and metastatic basal cell carcinoma
- Review the evidence for cemiplimab in locally advanced and metastatic basal cell carcinoma
- Discuss neoadjuvant treatment with vismodegib for locally advanced basal cell carcinoma

10 minutes

### Questions

---

## BREAK

---

- 45 minutes **Pathologic Considerations in Melanoma**  
*Michael Carter, MD, PhD, FRCPC, Assistant Professor, Department of Pathology, Dalhousie University*  
Learning objectives:
- Review molecular profiles of different subtypes of melanoma
  - Describe reflex molecular testing of melanoma in Nova Scotia
  - Use cases to highlight the value of expanded genomic profiling in melanoma and related tumors

- 10 minutes **Questions**

- 35 minutes **Moderated Case Discussion with Scientific Planning Committee Chairs**  
*Jen Melvin, MD, MSc, FRCPC, Medical Oncologist QEII Health Sciences Centre*  
*Robyn Macfarlane, MD, FRCPC, Medical Oncologist QEII Health Sciences Centre*  
*Eve St-Hilaire, MD, FRCPC, Hematologist Oncologist Dr. Georges-L.-Dumont University Hospital Centre*
- 

## BREAK

---

- 40 minutes **Adjuvant therapy in melanoma**  
*Vanessa Bernstein, MD, Clinical Associate Professor, Division of Medical Oncology, University of British Columbia*  
Learning objectives:
- To discuss the current evidence behind adjuvant therapy in completely resected stage III and IV melanoma.
  - Immunotherapy options
  - Targeted therapy options
  - To discuss how to choose between targeted therapy and immunotherapy in patients with BRAF MT disease.
  - To discuss the emerging evidence behind adjuvant therapy in completely resected stage IIB melanoma.

- 10 minutes **Questions**

- 45 minutes **Systemic Therapy Considerations in Metastatic Melanoma/Non-cutaneous Melanoma**  
*Jen Melvin, MD, MSc, FRCPC, Medical Oncologist QEII Health Sciences Centre*  
Learning objectives:
- Review systemic treatment options in advanced/metastatic cutaneous melanoma.
  - Discuss systemic treatment of mucosal melanoma.
  - Review systemic treatment options in uveal melanoma.

- 10 minutes **Questions**

- 35 minutes **Moderated case discussion with Scientific Planning Committee Chairs**  
*Jen Melvin, MD, MSc, FRCPC, Medical Oncologist QEII Health Sciences Centre*  
*Robyn Macfarlane, MD, FRCPC, Medical Oncologist QEII Health Sciences Centre*  
*Eve St-Hilaire, MD, FRCPC, Hematologist Oncologist Dr. Georges-L.-Dumont University Hospital Centre*
- 

## CONCLUSION

---

## STUDY CREDITS

The livestream meeting was recorded on November 19th and is now available to paid participants for asynchronous viewing from November 23rd to December 21st. This activity would be eligible for 5.75 hours of Section 2 self-learning credits with the Royal College of Physicians and Surgeons.

## POST CONFERENCE RESOURCES

Subject to speaker permission, most presentations will be available in PDF format on the Dalhousie CPD website for a period of six months following the conference. Available presentations will be posted as received within two weeks and can be found at:

<https://medicine.dal.ca/departments/core-units/cpd/conferences/post-conference-resources.html>.

## THANK YOU TO OUR SPONSORS

*In keeping with CMA Guidelines, program content and selection of speakers are the responsibility of the planning committee. Support is directed toward the costs of the course and not to individual speakers.*

Bristol-Myers Squibb

Merck

Novartis

Pfizer

Sanofi